Uremic prururitus in dialysis patient. Pruritus
Conditions
Interventions
Intervention 1: first intervention group: the patients in this group are given 2 grams of Fumaria parviflora L. in the form of 6 capsules of 330 mg as two capsules three times a day and one placebo ca
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: The hemodialysis patient who has uncontrollable pruritus and now at least 1 week doesn't use any antipruritus medication who had pruritus for at least 6 weeks patient must have normal range phosphor and potassium in the past month Parathyroid Hormone (PTH) must be lower than 500 measured visual analogue scale (VAS) score must be four or more
Exclusion criteria
Exclusion criteria: They do not have liver disease, a history of convulsions, or a specific skin disease that causes itching, and they do not have hemolytic blood disease. Patients who complain of itching for the first time are not included in the study If the patient was taking medication that interacted with gabapentin or Fumaria parviflora L., he was not included in the study Those who are allergic to Fumaria parviflora L. or Gabapentin are not included in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Itching score in the 5-D pruritus questionnaire. Timepoint: Before the start of the intervention (the beginning of the study) and two months later (the end of the study). Method of measurement: 5D itch questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life score in DLQI questionnaire. Timepoint: Before the start of the intervention (the beginning of the study) and two months later (the end of the study). Method of measurement: DLQI quality of life questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHosseini Seyed Ali
Shiraz University of Medical Sciences
Outcome results
None listed